Mivacron (Mivacurium Chloride)

Mivacurium Chloride, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocker presented as an injectable solution for intravenous use. It is employed to facilitate endotracheal intubation, provide muscle relaxation during surgical procedures, and act as an adjunct to general anesthesia in adult patients.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured product handling and regulatory compliance through robust cold‑chain logistics and dedicated customer support.

Mivacron, a non‑depolarizing neuromuscular blocker, is used in clinical settings that require rapid and reversible muscle relaxation.

- Facilitation of endotracheal intubation: Provides rapid onset muscle relaxation to enable safe airway management. - Muscle relaxation during surgery: Maintains a controlled neuromuscular block throughout operative procedures. - Adjunct to anesthesia: Enhances the overall anesthetic plan by allowing lower doses of other agents.

Mivacron may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Transient flushing: Brief reddening of the skin, often self‑limiting. - Mild hypotension: Slight drop in blood pressure that usually resolves without intervention. - Tachycardia: Increased heart rate observed during induction. - Bronchospasm: Temporary narrowing of the airways, more common in reactive airway disease. - Nausea: Mild gastrointestinal discomfort post‑administration.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate emergency treatment. - Prolonged neuromuscular blockade: Extended muscle weakness beyond the expected duration. - Respiratory depression: Inadequate ventilation requiring assisted breathing. - Cardiac arrest: Rare but life‑threatening cardiac event. - Malignant hyperthermia trigger: Potential precipitant in susceptible individuals.

When using Mivacron, clinicians should observe specific safety measures.

- Assess neuromuscular function: Continuously monitor depth of block with peripheral nerve stimulators. - Evaluate pseudocholinesterase activity: Identify patients with genetic deficiency that may prolong effect. - Review concomitant medications: Avoid agents that may potentiate neuromuscular blockade. - Monitor cardiovascular status: Observe for hypotension or arrhythmias during infusion. - Prepare for emergency reversal: Have anticholinesterase agents and resuscitation equipment readily available. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Pseudocholinesterase inhibitors (e.g., echothiophate, pyridostigmine): May markedly prolong neuromuscular blockade. - Other neuromuscular blocking agents: Additive effects can lead to excessive paralysis.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: Potentiate blockade, requiring dose adjustment. - Magnesium sulfate: Enhances neuromuscular inhibition, especially in obstetric patients. - Inhalational anesthetics (e.g., sevoflurane): May increase the duration of muscle relaxation. - Calcium channel blockers: Can modestly augment blockade. - Anticholinesterase reversal agents: May shorten duration but require careful titration.